TARKA 180mg+2mg modified release capsules medication leaflet

C09BB10 verapamil + trandolapril • Cardiovascular system | Ace inhibitors, combinations | Ace inhibitors and calcium channel blockers

The combination of verapamil and trandolapril is used for the treatment of hypertension and cardiovascular diseases, particularly in patients who require both a calcium channel blocker and an angiotensin-converting enzyme (ACE) inhibitor. Verapamil is a calcium channel blocker that relaxes blood vessels and reduces heart rate, improving blood flow and lowering blood pressure. Trandolapril is an ACE inhibitor that reduces the production of angiotensin II, a hormone that causes blood vessel constriction.

This combination is administered orally, usually once daily, and the dosage is adjusted based on the patient's response and blood pressure levels. It is important for patients to adhere to the treatment and regularly monitor their blood pressure.

Common side effects include dizziness, headaches, nausea, and fatigue. In rare cases, severe adverse reactions such as severe hypotension, hyperkalemia, or allergic reactions may occur.

The combination of verapamil and trandolapril provides an effective option for managing hypertension and cardiovascular diseases, helping to reduce the risk of complications such as myocardial infarction or stroke.

General data about TARKA 180mg+2mg

Substance: verapamil + trandolapril

Date of last drug list: 01-07-2013

Commercial code: W41507001

Concentration: 180mg+2mg

Pharmaceutical form: modified release capsules

Quantity: 28

Product type: original

Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Pharmaceutical forms available for verapamil + trandolapril

Concentrations available for verapamil + trandolapril

180mg+2mg, 180mg/2mg, 240mg/2mg, 240mg/4mg